Keros Therapeutics doses first patient in Phase 2 DMD rinvatercept trial

September 28, 2026 8:00 AM

Keros Therapeutics, Inc. (Nasdaq: KROS) announced that the first patient has been dosed in its Phase 2 clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found